関連する実験動画
Updated: Apr 17, 2026

13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.4K
キナーゼのダイナミクス. 古代のタンパク質キナーゼを用いて,現代のがん薬のメカニズムを解明する
C Wilson1, R V Agafonov1, M Hoemberger1
1Howard Hughes Medical Institute and Department of Biochemistry, Brandeis University, Waltham, MA 02452, USA.
まとめ
腫瘍遺伝子のSrcとAblの進化的再構築は,ガン薬のGleevecがどのようにして特異性を獲得したかを明らかにしています. この研究は,Gleevecの背後にある原子化メカニズムを詳細に説明しています.
科学分野:
- バイオケミストリー バイオケミストリー
- 進化生物学の進化生物学について
- 構造生物学 構造生物学とは
背景:
- タンパク質の機能はエネルギー風景によって支配され,進化はこれらの風景を変えることで変化します.
- 人間の腫瘍遺伝子SrcとAblは共通の祖先を共有し,研究するための進化的経路を提供します.
- 腫瘍遺伝子の進化を理解することは,標的がん治療の開発に不可欠です.
研究 の 目的:
- SrcとAblの腫瘍遺伝子の間の進化の経路を再現する.
- 進化的再構築を通して,Gleevecの選択性の原子的メカニズムを解明する.
- エネルギー環境がどのように進化し,薬物特異性に影響を与えるかを理解する.
主な方法:
- SrcとAblの腫瘍遺伝子の共通の祖先を再構築する.
- 再構築された共通の祖先のX線構造を決定する.
- 静止状態以前の運動分析を行う.
主要な成果:
- Ablへの進化軌道は,Gleevecの親和性を獲得したが,Srcへの進化軌道は,Gleevecの親和性を失った.
- Gleevecの特異性の重要なメカニズムは,誘発的適合均衡のシフトを含む.
- この誘導的適合均衡は,T315I抵抗変異にも関係しています.
結論:
- この研究は,Gleevecの進化的利益を追跡することによって,Gleevecの特異性の正確なメカニズムを明らかにしています.
- タンパク質エネルギー環境における進化的変化が,薬物と標的の相互作用を決定する.
- エネルギー景観の進化に関する洞察は,薬剤耐性を理解し,新しい治療法を設計するための枠組みを提供します.
関連する概念動画
M-Cdk Drives Transition Into Mitosis
6.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression
1.8K
1.8K
Inhibition of Cdk Activity
6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Protein Kinases and Phosphatases
15.7K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.7K
Protein Kinases and Phosphatases
4.7K
4.7K

